Innate Pharma S.A is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Data Provided by Refinitiv. Minimum 15 minutes delayed.


Press Releases
22-Jun-21

Innate Pharma presents preliminary data from TELLOMAK trial showing clinical response for lacutamab in mycosis fungoides

Marseille, June 22, 2021 (GLOBE NEWSWIRE) -- First data set from TELLOMAK establish es safety, clinical response s and skin improvement in patients with mycosis fungoides that express KIR3DL2 Data support continued development of lacutamab for KIR3DL2-expressing T -c ell l ymphomas Results

16-Jun-21

Innate Pharma to Host Virtual Investor Event to Highlight Progress Against Company Strategy

Marseille, France, June 16, 2021 (GLOBE NEWSWIRE) -- Company to highlight lacutamab data in mycosis fungoides and share data on its next-generation NK cell engager platform, ANKET TM Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today

14-Jun-21

Number of Shares and Voting Rights of Innate Pharma as of June 1, 2021

Marseille, France, June 14, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (the “ Company ” - Euronext